NCT02355756View on ClinicalTrials.gov

Biomarker Development for Future PAC1 Antagonists With Maxadilan

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

Maxadilan

DRUG

Placebo

Trial Locations (1)

3000

Centre for Clinical Pharmacology, UZ Leuven, Leuven

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER

NCT02355756 - Biomarker Development for Future PAC1 Antagonists With Maxadilan | Biotech Hunter | Biotech Hunter